Over the past year, pharmacy benefit managers have deployed a new weapon against the widely used but controversial copay assistance programs that drug makers distribute to consumers. Clumsily called copay accumulators, these are raising a controversy of their own over concerns consumers will pay more for their medicines. And drug makers, meanwhile, worry about a big financial hit.

These accumulators, which target specialty medicines that are typically more expensive and are often injected or infused, do not count the value of any coupons toward out-of-pocket medicine costs that are applied toward deductibles. As a result, these accumulators are expected to cause drug spending to drop, according to Adam Fein, who wrote a useful primer on his Drug Channels blog

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy